Aadi Bioscience, Inc

Biotechnology ResearchUnited States11-50 Employees

Aadi Bioscience Inc. (Aadi) is a biopharmaceutical company focused on precision therapies for genetically-defined cancers. 

We strive to unleash the potential of mTOR inhibition by employing precision medicine & nanoparticle technology to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Our lead product has been FDA-approved for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PEComa).

In March 2025, we became a wholly-owned subsidiary of KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan. A science-first mindset and patient-centric approach is always in our genes. Together with KAKEN, we continue to dedicate to developing products for cancers with mTOR pathway driver alterations.

For more information, please visit: https://aadibio.com/ and https://www.kaken.co.jp/english/.

Sign up for free to view info

Email Format Employee directory